PVLA Long Put Strategy
PVLA (Palvella Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
PVLA (Palvella Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.75B, a beta of -0.14 versus the broader market, a 52-week range of 21.55-151.18, average daily share volume of 247K, a public-listing history dating back to 2015, approximately 14 full-time employees. These structural characteristics shape how PVLA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of -0.14 indicates PVLA has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a long put on PVLA?
A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration.
Current PVLA snapshot
As of June 29, 2026, spot at $152.87, ATM IV 58.90%, IV rank 1.94%, expected move 16.89%. The long put on PVLA below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this long put structure on PVLA specifically: PVLA IV at 58.90% is on the cheap side of its 1-year range, which favors premium-buying structures like a PVLA long put, with a market-implied 1-standard-deviation move of approximately 16.89% (roughly $25.81 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated PVLA expiries trade a higher absolute premium for lower per-day decay. Position sizing on PVLA should anchor to the underlying notional of $152.87 per share and to the trader's directional view on PVLA stock.
PVLA long put setup
The PVLA long put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With PVLA near $152.87, the first option leg uses a $155.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed PVLA chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 PVLA shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Put | $155.00 | $7.65 |
PVLA long put risk and reward
- Net Premium / Debit
- -$765.00
- Max Profit (per contract)
- $14,734.00
- Max Loss (per contract)
- -$765.00
- Breakeven(s)
- $147.35
- Risk / Reward Ratio
- 19.260
Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium.
PVLA long put payoff curve
Modeled P&L at expiration across a range of underlying prices for the long put on PVLA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$14,734.00 |
| $33.81 | -77.9% | +$11,354.07 |
| $67.61 | -55.8% | +$7,974.14 |
| $101.41 | -33.7% | +$4,594.21 |
| $135.21 | -11.6% | +$1,214.28 |
| $169.01 | +10.6% | -$765.00 |
| $202.81 | +32.7% | -$765.00 |
| $236.61 | +54.8% | -$765.00 |
| $270.40 | +76.9% | -$765.00 |
| $304.20 | +99.0% | -$765.00 |
When traders use long put on PVLA
Long puts on PVLA hedge an existing long PVLA stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying PVLA exposure being hedged.
PVLA thesis for this long put
The market-implied 1-standard-deviation range for PVLA extends from approximately $127.06 on the downside to $178.68 on the upside. A PVLA long put expresses a directional view that the underlying closes below the strike minus premium at expiration, frequently sized to hedge an existing long PVLA position with one put per 100 shares held. Current PVLA IV rank near 1.94% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on PVLA at 58.90%. As a Healthcare name, PVLA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to PVLA-specific events.
PVLA long put positions are structurally bearish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. PVLA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move PVLA alongside the broader basket even when PVLA-specific fundamentals are unchanged. Long-premium structures like a long put on PVLA are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current PVLA chain quotes before placing a trade.
Frequently asked questions
- What is a long put on PVLA?
- A long put on PVLA is the long put strategy applied to PVLA (stock). The strategy is structurally bearish: A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration. With PVLA stock trading near $152.87, the strikes shown on this page are snapped to the nearest listed PVLA chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are PVLA long put max profit and max loss calculated?
- Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium. For the PVLA long put priced from the end-of-day chain at a 30-day expiry (ATM IV 58.90%), the computed maximum profit is $14,734.00 per contract and the computed maximum loss is -$765.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a PVLA long put?
- The breakeven for the PVLA long put priced on this page is roughly $147.35 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current PVLA market-implied 1-standard-deviation expected move is approximately 16.89%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long put on PVLA?
- Long puts on PVLA hedge an existing long PVLA stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying PVLA exposure being hedged.
- How does current PVLA implied volatility affect this long put?
- PVLA ATM IV is at 58.90% with IV rank near 1.94%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.